Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma

NCT00540930 is registered in ClinicalTrials.gov with Shields, Shields and Associates as lead sponsor.

NCT NCT00540930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00540930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma
Lead sponsor
Shields, Shields and Associates
Phase
Phase 4
Overall status
Unknown status
Start date
April 30, 2007
Completion date
April 30, 2009
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

radiation maculopathy, radiation retinopathy, uveal melanoma